The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Abstract
BACKGROUND: Diagnosis of Creutzfeldt-Jakob disease (CJD) is made according to the typical clinical picture and can be supported by a positive 14-3-3 CSF immunoblot. Promising results for the diagnostic sensitivity and specificity of tau-protein measurement in CSF already have been described in a smaller group of patients. Both tests in a larger group of patients with the differential diagnosis of CJD were evaluated. METHODS: CSF of 297 patients under the differential diagnosis of CJD (109 definite, 55 probable, 39 possible; 85 others, 1 iatrogenic, 8 genetic), 23 nondemented control subjects, and 15 non-CJD patients with positive 14-3-3 immunoblots were analyzed. The 14-3-3 immunoblot bands were semiquantitatively rated as strong, medium, and weak. Tau-protein was analyzed using a commercially available ELISA. In addition, patients were neuropathologically classified according to prion protein type and polymorphism at codon 129. RESULTS: A diagnostic sensitivity of 94%, a diagnostic specificity of 90%, and a positive predictive value of 92% were achieved for tau-protein at a cut-off of 1,300 pg/mL. These results are comparable with those of the 14-3-3 immunoblot. For patients with type II prion protein and methionine/valine or valine/valine polymorphism at codon 129, tau-protein has a higher diagnostic sensitivity than 14-3-3 protein. Tau-protein levels were significantly higher in patients with higher-rated 14-3-3 immunoblot bands. CONCLUSION: The differential diagnostic significance of the 14-3-3 immunoblot is similar to that of the tau-protein ELISA. The advantage of the tau-protein ELISA is that it is easy to use in routine laboratories. Patients with a negative 14-3-3 immunoblot already have measurable tau-protein levels. This increases information on 14-3-3-negative patients with CJD and especially on patients with other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
14-3-3 Proteins: Structure, Function, and Regulation
Fu, H., Subramanian, R. R., & Masters, S. C. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.617 · Cited by 1,579
Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease
Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S. G., Farlow, M., Dickson, D. W., Sima, A. A. F., Trojanowski, J. Q., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390613 · Cited by 864
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationReduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Hill, A., Butterworth, R., Joiner, S., Jackson, G., Rossor, M., Thomas, D., Frosh, A., Tolley, N., Bell, J., Spencer, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12075-5 · Cited by 699
Hsich, G., Kenney, K., Gibbs, C. J., Lee, K. H., & Harrington, M. G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351303 · Cited by 660
Masters, C. L., Harris, J. O., Gajdusek, D. C., Gibbs, C. J., Bernoulli, C., & Asher, D. M. (1979) · Annals of Neurology · doi:10.1002/ana.410050212 · Cited by 629
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Van de Voorde, A., Martin, J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 495
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 488
Zerr, I., Bodemer, M., Gefeller, O., Otto, M., Poser, S., Wiltfang, J., Windl, O., Kretzschmar, H. A., & Weber, T. (1998) · Annals of Neurology · doi:10.1002/ana.410430109 · Cited by 456
Self-citationElevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 341
Self-citationKanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C. M., Lee, V. M. ‐., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 298
Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease
Kretzschmar, H. A., Ironside, J. W., DeArmond, S. J., & Tateishi, J. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550090125018 · Cited by 288
Self-citationAccuracy and Reliability of Periodic Sharp Wave Complexes in Creutzfeldt-Jakob Disease
Steinhoff, B. J., Racker, S., Herrendorf, G., Poser, S., Grosche, S., Zerr, I., Kretzschmar, H., & Weber, T. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020074017 · Cited by 281
Self-citationItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256
Self-citationAitken, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)88971-9 · Cited by 251
Bieschke, J., Giese, A., Schulz-Schaeffer, W., Zerr, I., Poser, S., Eigen, M., & Kretzschmar, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5468 · Cited by 240
Self-citationAndreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Raiha, I., Sourander, L., Winblad, B., & Blennow, K. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227
Vigo-Pelfrey, C., Seubert, P. P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B., Lieberburg, I., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225
14-3-3ζ Is an Effector of Tau Protein Phosphorylation
Hashiguchi, M., Sobue, K., & Paudel, H. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003738200 · Cited by 223
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
Andreasen, N., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1488 · Cited by 212
Current clinical diagnosis in Creutzfeldt-Jakob disease: Identification of uncommon variants
Zerr, I., Schulz-Schaeffer, W. J., Giese, A., Bodemer, M., Schröter, A., Henkel, K., Tschampa, H. J., Windl, O., Pfahlberg, A., Steinhoff, B. J., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<323::aid-ana6>3.0.co;2-5 · Cited by 189
Self-citationNeurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins
Layfield, R., Fergusson, J., Aitken, A., Lowe, J., Landon, M., & Mayer, R. J. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12598-2 · Cited by 188
Beaudry, P., Cohen, P., Brandel, J. P., Delasnerie-Lauprêtre, N., Richard, S., Launay, J. M., & Laplanche, J. L. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017095 · Cited by 183
Molecular genetics of human prion diseases in Germany
Windl, O., Giese, A., Schulz‐Schaeffer, W., Zerr, I., Skworc, K., Arendt, S., Oberdieck, C., Bodemer, M., Poser, S., & Kretzschmar, H. A. (1999) · Human Genetics · doi:10.1007/s004390051096 · Cited by 181
Self-citationGreen, A. J. E. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.744 · Cited by 179
Kohnken, R., Buerger, K., Zinkowski, R., Miller, C., Kerkman, D., DeBernardis, J., Shen, J., Möller, H.-J., Davies, P., & Hampel, H. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173
Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Otto, M., Esselmann, H., Schulz-Schaeffer, W., Neumann, M., Schröter, A., Ratzka, P., Cepek, L., Zerr, I., Steinacker, P., Windl, O., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1099 · Cited by 171
Self-citationZerr, I., Bodemer, M., Räcker, S., Grosche, S., Poser, S., Weber, T., & Kretzschmar, H. A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90118-3 · Cited by 165
Self-citationHyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease
Buée‐Scherrer, V., Hof, P. R., Buée, L., Leveugle, B., Vermersch, P., Perl, D. P., Olanow, C. W., & Delacourte, A. (1996) · Acta Neuropathologica · doi:10.1007/s004010050436 · Cited by 158
Increased cerebrospinal fluid tau in patients with Alzheimer's disease
Jensen, M., Basun, H., & Lannfelt, L. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11297-a · Cited by 131
Epidemiology of Creutzfeldt-Jakob disease
Will, R. G. (1993) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072655 · Cited by 129
Otto, M., Wiltfang, J., Schütz, E., Zerr, I., Otto, A., Pfahlberg, A. B., Gefeller, O., Uhr, M., Giese, A., Weber, T., et al. (1998) · BMJ · doi:10.1136/bmj.316.7131.577 · Cited by 116
Self-citationKenney, K., Brechtel, C., Takahashi, H., Kurohara, K., Anderson, P., & Gibbs, C. J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<395::aid-ana18>3.0.co;2-a · Cited by 68
Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies
Weber, T., Otto, M., Bodemer, M., & Zerr, I. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)89430-9 · Cited by 46
Self-citationTau Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia
Ingelson, M., Blomberg, M. E., Benedikz, E., Wahlund, L., Karlsson, E., Vanmechelen, E., & Lannfelt, L. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017187 · Cited by 36
Parchi, P., Giese, A., Capellari, S., Brown, P., Schulz-Schaeffer, W., Windl, O., Zerr, I., Budka, H., Kopp, N., Piccardo, P., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<224::aid-ana12>3.0.co;2-w
Self-citation(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Cited by
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Sporadic and familial CJD: classification and characterisation
Gambetti, P., Kong, Q., Zou, W., Parchi, P., & Chen, S. G. (2003) · British Medical Bulletin · doi:10.1093/bmb/66.1.213 · Cited by 569
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Metadata
- Authors
- Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz–Schaeffer, W., Kretzschmar, H. A., & Poser, S.
- Venue
- Neurology
- Published
- 2002-01-22
- Volume
- 58
- Issue
- 2
- Pages
- 192-197
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2014116107
- Cited by
- 289
- References
- 40
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.